<DOC>
	<DOCNO>NCT00667576</DOCNO>
	<brief_summary>The purpose study investigate initial dose dose adjustment range paricalcitol injection patient chronic kidney disease hemodialysis secondary hyperparathyroidism .</brief_summary>
	<brief_title>Dose-response Study Paricalcitol Injection Chronic Kidney Disease Patients Receiving Hemodialysis</brief_title>
	<detailed_description>This multicenter , randomize , open-label trial consist 4 dose-adjustment regimen paricalcitol injection ( initial dos dose adjustment range 2 ± 1 µg , 2 ± 2 µg , 4 ± 1 µg , 4 ± 2 µg ) 1 maxacalcitol regimen ( initial dose dose adjustment range 5 µg ± 2.5 µg 10 µg ± 2.5 µg ) reference group . Subjects met inclusion criterion randomize equally 1 treatment group iPTH value screen ( &lt; 500 pg/mL ≥ 500 pg/mL ) dynamic allocation factor . Study drug administer 3 time weekly ( every day ) venous end hemodialysis circuit completion dialysis session . The initial dos continue 2 week , follow dose adjustment ( increase , maintenance , decrease , suspension , resumption ) 1 µg 2 µg unit paricalcitol group 2.5 µg unit maxacalcitol group base iPTH , calcium ( adjust ) , phosphorus value every 2 week . Subjects paricalcitol group suspend treatment iPTH value decrease &lt; 60 pg/mL accordance guideline propose Japanese Society Dialysis Therapy treatment secondary hyperparathyroidism chronic dialysis patient ( control goal value 60-180 pg/mL iPTH ) . The dose adjustment criterion base iPTH value maxacalcitol group set accord prescribe information maxacalcitol ( suspend iPTH decrease ≤ 150 pg/mL ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Maxacalcitol</mesh_term>
	<criteria>Diagnosed chronic kidney disease receive hemodialysis 3 time week least 3 month prior obtain inform consent schedule receive hemodialysis study period . Using dialysate constant concentration calcium 4 week prior obtain inform consent phosphate binder constant dose regimen 2 week prior obtain inform consent . Intact parathyroid hormone level ( iPTH ) ≥ 300 pg/mL Calcium ( adjust ) 8.410.2 milligrams/deciliter ( mg/dL ) Phosphorus ≤ 6.5 mg/dL Age ≥ 20 year History allergic reaction significant sensitivity vitamin D vitamin D relate compound Parathyroidectomy ethanol infusion within past year Progressive malignancy clinically significant hepatic disease , severe cerebral/cardiovascular disease , severe hypertension , uncontrolled diabetes mellitus Drug alcohol abuse within past 6 month Taking calcitonin , maintenance intravenous oral glucocorticoid , cinacalcet , bisphosphonates , selective estrogenreceptor modulator ( SERM ) , vitamin D compound ( study drug ) , drug may affect calcium bone metabolism ( estrogen progestin , vitamin K2 ) Will need take chronic dose ( ≥ 2 consecutive week ) cytochrome P450 ( CYP3A ) inhibitor ( e.g. , clarithromycin , grapefruit product ) inducer ( e.g. , carbamazepine , rifampicin ) Taking aluminum contain product ( 2 week prior consent )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>secondary hyperparathyroidism</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>paricalcitol</keyword>
	<keyword>maxacalcitol</keyword>
</DOC>